NIAID grants fund to VaxInnateIllustrative image – not actual.

The National Institute of Allergy and Infectious Diseases (NIAID) has granted $2.2 million fund to New Jersey based VaxInnate Corporation for developing a recombinant vaccine for the prevention of dengue.


NIAID, a part of US National Institutes of Health (NIH), has granted fund for three years to provide a recombinant tetravalent dengue vaccine using VaxInnate’s proprietary technology. The technology includes genetically fusing vaccine antigens to the bacterial protein flagellin, a potent stimulator of the innate immune system, which dramatically improves the potency, manufacturing capacity and cost-effectiveness of vaccines.
 


 

← All latest storiesBack to top →